Myc overexpression brings out unexpected antiapoptotic effects of miR-34a

Oncogene

Volumn 30, Issue 22, 2011, Pages 2587-2594

  Sotillo, E ^a   Laver, T ^b   Mellert, H ^b   Schelter, J M ^c,e   Cleary, M A ^c,e   McMahon, S ^b,d   Thomas Tikhonenko, A ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROSETTA INPHARMATICS   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

microRNA; Myc; p53

Indexed keywords

ARF PROTEIN; BORTEZOMIB; MICRORNA; MICRORNA 34A; MYC PROTEIN; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADP-RIBOSYLATION FACTORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957891891     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.634     Document Type: Article

References (58)

1. Adachi N, So S, Iiizumi S, Nomura Y, Murai K, Yamakawa C et al. (2006). The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination. DNA Cell Biol 25: 19-24. (Pubitemid 43089749)
2. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI et al. (2007). Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336. (Pubitemid 46203961)
3. Bagchi A, Mills AA. (2008). The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556. (Pubitemid 351556249)
4. Barak Y, Juven T, Haffner R, Oren M. (1993). mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468. (Pubitemid 23073692)
5. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
6. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT. (1992). The pattern of p53 mutations in Burkitts lymphoma differs from that of solid tumors. Cancer Res 52: 4273-4276.
7. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307. (Pubitemid 47176893)
8. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. (1995). The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromo-some stability. Genes Dev 9: 2888-2902.
9. Calin GA, Croce CM. (2007). Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 117: 2059-2066. (Pubitemid 47219545)
10. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529. (Pubitemid 35403967)
11. Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC et al. (2010). p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci USA 107: 5375-5380.
12. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752. (Pubitemid 46856245)
13. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
14. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M et al. (2009). Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 106: 3384-3389.
15. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M et al. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 17: 236-245.
16. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM et al. (2008). A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6: 735-742.
17. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. (2007). MicroRNA-34b and MicroRNA-34c are targets ofp53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433-8438. (Pubitemid 47437414)
18. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK et al. (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128.
19. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. (2009). Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci 50: 4542-4551.
20. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065. (Pubitemid 44325933)
21. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH et al. (2009). Guidelines for the use and interpreta-tion of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107.
22. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D et al. (2010). microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9: 1031-1036.
23. He L, He X, Lim LP, de SE, Xuan Z, Liang Y et al. (2007a). A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134. (Pubitemid 47014436)
24. He L, He X, Lowe SW, Hannon GJ. (2007b). microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 7: 819-822. (Pubitemid 350006254)
25. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. (2005). A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
26. Junttila MR, Evan GI. (2009). p53-a Jack of all trades but master of none. Nat Rev Cancer 9: 821-829.
27. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. (2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
28. Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL et al. (2008). The mechanism of micro-RNA-mediated transla-tion repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 105: 8866-8871.
29. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E et al. (2009). miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 35: 610-625.
30. Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN. (2009). Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J28: 3157-3170.
31. Lindstrom MS, Klangby U, Wiman KG. (2001). p14ARF homo-zygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 20: 2171-2177. (Pubitemid 32424011)
32. Lindstrom MS, Wiman KG. (2002). Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12: 381-387.
33. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR et al. (2007). Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27: 2240-2252. (Pubitemid 46418479)
34. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
35. Luan S, Sun L, Huang F. (2010). MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res 41: 67-74.
36. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. (2006). A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217. (Pubitemid 44380294)
37. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P et al. (2009). Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806-2811.
38. Navarro F, Gutman D, Meire E, Caceres M, Rigoutsos I, Bentwich Z et al. (2009). miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 114: 2181-2192.
39. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843. (Pubitemid 40839736)
40. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C et al. (2009). miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
41. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S et al. (2004). Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64: 3087-3095. (Pubitemid 38581408)
42. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS et al. (2000). Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer 87: 787-793. (Pubitemid 30660555)
43. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743. (Pubitemid 46856247)
44. Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A. In: Bettuzzi S and Pucci S (eds). Advances in Cancer Research, Volume 105: Clusterin, part B. Elsevier: USA, 2009, pp 116-127.
45. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M et al. (2001). The transcriptional program of a human B cell line in response to Myc Nucl Acids Res 29: 397-406. (Pubitemid 32060926)
46. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS et al. (2006). Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841-851. (Pubitemid 44960096)
47. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A et al. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593. (Pubitemid 47327945)
48. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. (Pubitemid 38174664)
49. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK et al. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159. (Pubitemid 33035942)
50. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. (2008). Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886. (Pubitemid 351312807)
51. Welch C, Chen Y, Stallings RL. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022. (Pubitemid 47172643)
52. Wu X, Bayle JH, Olson D, Levine AJ. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132. (Pubitemid 23207405)
53. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J et al. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414. (Pubitemid 351405110)
54. Yamakuchi M, Ferlito M, Lowenstein CJ. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426.
55. Yamakuchi M, Lowenstein CJ. (2009). MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8: 712-715.
56. Yu D, Carroll M, Thomas-Tikhonenko A. (2007). p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood 109: 4936-4943. (Pubitemid 46827792)
57. Yu D, Dews M, Park A, Tobias JW, Thomas-Tikhonenko A. (2005). Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res 65: 5454-5461. (Pubitemid 40834291)
58. Yu D, Thomas-Tikhonenko A. (2002). A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21: 1922-1927. (Pubitemid 34259195)